<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633020</url>
  </required_header>
  <id_info>
    <org_study_id>CELIM-RCD-002</org_study_id>
    <secondary_id>2015-004063-36</secondary_id>
    <nct_id>NCT02633020</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol CELIM-RCD-002 is designed to be a Phase 2a randomized, double-blind,
      placebo-controlled, parallel group study to evaluate the efficacy and safety of AMG 714 for
      the treatment of adult patients with Type II Refractory Celiac Disease (RCD-II), an in situ
      small bowel T cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological Response: Reduction from baseline in the % of aberrant small bowel intestinal intraepithelial lymphocytes (surface CD3- intracellular CD3+)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Reduction from baseline in the % of aberrant intestinal intraepithelial lymphocytes, measured by flow cytometry after small intestinal biopsy collection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological Response: Improvement from baseline in small intestinal morphology as measured by the Vh:Cd ratio</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The Villous Height to Crypt Depth ratio (Vh:Cd) will be used in intestinal biopsy material</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response: Change from baseline in clinical symptoms as measured by the GSRS</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The main secondary patient reported outcome used will be the GSRS (Gastrointestinal Symptom Rating Scale).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability: Number of participants with treatment-related adverse events as assessed by CTCAE</measure>
    <time_frame>12 weeks</time_frame>
    <description>The frequency and nature of adverse events will be collected and analyzed</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type II Refractory Celiac Disease (RCD-II)</condition>
  <condition>In Situ Small Bowel T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>AMG 714 8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 714 IV every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMG 714</intervention_name>
    <description>A fully human anti-IL-15 monoclonal antibody</description>
    <arm_group_label>AMG 714 8 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of refractory celiac disease Type 2 (RCD-II)

          -  Greater than 20% aberrant intraepithelial lymphocytes (IEL) as assessed by flow
             cytometry

          -  On a gluten-free diet for at least 6 months

          -  Avoid pregnancy

        Exclusion Criteria:

          -  Enteropathy-Associated T cell Lymphoma (EATL)

          -  Infections

          -  Immune suppression

          -  Clinically significant co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Cellier, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Européen Georges-Pompidou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Mulder, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VUmc Amsterdam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.celimmune.com</url>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 3, 2017</lastchanged_date>
  <firstreceived_date>November 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in peer-reviewed journals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
